5 of Last Week's Biggest Losers
Jan 30th 2012 9:56AM
Updated Jan 30th 2012 9:58AM
There's never a shortage of losers in the stock market.
Let's take a closer look at five of this past week's biggest sinkers.
|Jan. 27||Weekly Loss||My Watchlist|
|Infinity Pharmaceuticals (NAS: INFI)||$5.98||(40%)||Add|
|Inergy (NYS: NRGY)||$17.33||(23%)||Add|
|Carbo Ceramics (NYS: CRR)||$102.07||(20%)||Add|
|Momenta Phramaceuticals (NAS: MNTA)||$15.19||(20%)||Add|
|Monster Worldwide (NYS: MWW)||$7.35||(18%)||Add|
Infinity Pharmaceuticals was the market's biggest loser, shedding 40% of its value after revealing disappointing clinical trial results for its advanced pancreatic cancer treatment. Small biotechs can post big gains when a promising drug bears fruit, but limited pipelines can backfire when things go wrong.
Inergy ran out of energy on fears that it may have to slash its dividend. The propane distributor hit a fresh 52-week low after revealing that cash flows last year were only good enough to cover 68% of its distributions as warm weather ate into propane demand.
Carbo Ceramics stumbled after posting quarterly revenue and earnings that were well below what analysts had been targeting.
Momenta Pharmaceuticals took a hit after a federal appeals court decided to stay an injunction that would have banned a rival from selling a competing generic blood thinner in the United States.
Monster Worldwide had a monster of an announcement, revealing that it will have to let go 400 of its employees -- or 7% of its workforce -- after a disappointing quarter. There may be a punch line waiting in a tidbit on an online recruiter going for layoffs of its own, but pink slips aren't funny.
It was a rough week for these five stocks. If you want to shake yesterday's losers and ride tomorrow's winners, a new special report reveals Motley Fool's top stock for 2012. It's free, but only for a limited time, so check it out now.
At the time this article was published The Motley Fool owns shares of Momenta Pharmaceuticals. Motley Fool newsletter services have recommended buying shares of Momenta Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.